Literature DB >> 9113104

Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol.

J C Knutson1, L W LeVan, C R Valliere, C W Bishop.   

Abstract

1 alpha,24-Dihydroxyvitamin D2 (1 alpha,24(OH)2D2) is a metabolite of 1 alpha-hydroxyvitamin D2 (1 alpha-OH-D2), a prodrug in development as a treatment for secondary hyperparathyroidism occurring in end stage renal disease. This prodrug has a broader therapeutic index than the corresponding vitamin D3 analogue, possibly because hepatic metabolism of 1 alpha-OH-D2 shifts at higher dose levels from 1 alpha,25-dihydroxyvitamin D2 (1 alpha,25(OH)2D2) to 1 alpha,24(OH)2D2. In this report, we present the pharmacokinetics of 1 alpha,24(OH)2D2 and its systemic effects on serum and urine calcium in rats. These properties were compared with those of 1 alpha,25(OH)2D2, calcitriol, the active metabolite of endogenous vitamin D3, and calcipotriol, a vitamin D analogue noted for its rapid clearance and minimal effect on calcium homeostasis. Comparison of the blood concentration curves from time zero to infinity indicated that 1 alpha,24(OH)2D2 had about one-fifth the systemic exposure of 1 alpha,25(OH)2D2 or calcitriol, but almost 30 times that of calcipotriol. The oral bioavailabilities and circulating half-lives of 1 alpha,24(OH)2D2 and calcitriol were similar, whereas those of calcipotriol were much less. In vitamin D-deficient rats, oral doses of 1 alpha,25(OH)2D2 and calcitriol produced similar dose-dependent increases in serum calcium, whereas an oral dose 30 times greater was required for 1 alpha,24(OH)2D2 to produce a similar response. Dose-response curves generated after oral and subcutaneous administration of 1 alpha,24(OH)2D2, calcitriol, and calcipotriol to normal rats indicated that 1 alpha,24(OH)2D2 increases serum and urine calcium to a much lesser extent than calcitriol, and to a slightly greater extent than calcipotriol. These properties of 1 alpha,24(OH)2D2 suggest that production of this metabolite from 1 alpha-OH-D2 contributes to the lowered toxicity of 1 alpha-OH-D2 and indicate that 1 alpha,24(OH)2D2 contributes to the lowered toxicity of 1 alpha-OH-D2 and indicate that 1 alpha,24(OH)2D2 itself has therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9113104     DOI: 10.1016/s0006-2952(97)00004-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  The epithelial calcium channels TRPV5 and TRPV6: regulation and implications for disease.

Authors:  Monique van Abel; Joost G J Hoenderop; René J M Bindels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04       Impact factor: 3.000

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

4.  1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.

Authors:  R St-Arnaud; A Arabian; V W C Yu; O Akhouayri; J C Knutson; S A Strugnell
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 5.  New Vitamin D analogues for osteodystrophy in chronic kidney disease.

Authors:  John Cunningham
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

Review 6.  The serum vitamin D metabolome: What we know and what is still to discover.

Authors:  Robert C Tuckey; Chloe Y S Cheng; Andrzej T Slominski
Journal:  J Steroid Biochem Mol Biol       Date:  2018-09-08       Impact factor: 4.292

7.  Maternal Vitamin D Prevents Abnormal Dopaminergic Development and Function in a Mouse Model of Prenatal Immune Activation.

Authors:  Wei Luan; Luke Alexander Hammond; Stephanie Vuillermot; Urs Meyer; Darryl Walter Eyles
Journal:  Sci Rep       Date:  2018-06-27       Impact factor: 4.379

8.  Pulmonary activation of vitamin D3 and preventive effect against interstitial pneumonia.

Authors:  Ichiro Tsujino; Ryoko Ushikoshi-Nakayama; Tomoe Yamazaki; Naoyuki Matsumoto; Ichiro Saito
Journal:  J Clin Biochem Nutr       Date:  2019-09-11       Impact factor: 3.114

9.  PTH suppression by calcitriol does not predict off-target actions in experimental CKD.

Authors:  Bruno A Svajger; Cynthia M Pruss; Kimberly J Laverty; Jason G E Zelt; Glenville Jones; Martin Kaufmann; Martin Petkovich; Rachel M Holden; Michael A Adams
Journal:  Pharmacol Res Perspect       Date:  2020-06

10.  DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways.

Authors:  Zaid H Maayah; Ti Zhang; Marcus Laird Forrest; Samaa Alrushaid; Michael R Doschak; Neal M Davies; Ayman O S El-Kadi
Journal:  Pharmaceutics       Date:  2018-09-04       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.